Presentations are now available by clicking the links below…
Program Overview and Objectives
Peter Greenberg
Update of WHO and Molecular Classifications in MDS
Mario Cazzola
Therapeutic and Prognostic Role of Epigenetic Abnormalities in MDS
Stephen Nimer
Impact of Comorbidity on Quality of Life and Clinical Outcomes in MDS
Peter Valent
Myeloid-derived Suppressor Cells and Altered Innate Immunity Contribution to MDS Pathogenesis
Alan List
Recent developments in clinical classification, epigenetic treatment and hematopoietic stem cell transplantation have generated valuable advances for aiding management of patients with myelodysplastic syndromes (MDS). Determining the impact of patient comorbidity and quality of life inform the use of these therapeutic approaches. These issues will be discussed as well as recent biologic data describing the role of altered marrow microenvironmental innate immunity involved in improved understanding of pathogenetic lesions underlying this disease.
This activity is intended for physicians, oncology nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals interested in the treatment and management of patients with Myelodysplastic Syndromes.
Professor of Hematology
University of Pavia School of Medicine
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
Professor of Medicine, University of Washington
Member, Fred Hutchinson Cancer Research Center
Seattle, WA
Professor of Medicine
Stanford University Cancer Center
Stanford, CA
President and CEO
Frank and Carol Morsani Endowed Chair
H. Lee Moffitt Cancer Center
and Research Institute
Tampa, Florida
Director, Sylvester Comprehensive Cancer Center
Professor of Medicine, Biochemistry & Molecular Biology
University of Miami Miller School of Medicine
Miami, Florida
Department of Internal Medicine I
Division of Hematology & Hemostaseology
Scientific Chair – Ludwig Boltzmann Cluster Oncology
Medical University of Vienna
Vienna, Austria